Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) headquartered in San Diego, will host a conference call for the investment community to discuss the 3Q20 financial results on 30th October 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.ligand.com
Earnings Expectation
Ligand Pharmaceuticals Incorporated is reporting third quarter earnings results on Friday 30th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.98 per share from $ 44.36 million in revenue. For the full year, analysts predict revenues of $ 170.22 million, while looking forward to income of $ 3.91 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 170.00 million ~ $ 170.00 million, where as bottomline are predicted in a range of $ 3.95 ~ $ 3.95 per share
Click Here For More Historical Outlooks Of Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The companys partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others.
